Screener
Iovance Biotherapeutics, Inc. IOVA Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Iovance Biotherapeutics, Inc.’s reported figures.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
FAQ
- What is Iovance Biotherapeutics, Inc.'s free cash flow?
- Iovance Biotherapeutics, Inc. (IOVA) reported free cash flow of -$66.28M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s free cash flow changed year-over-year?
- Iovance Biotherapeutics, Inc.'s free cash flow increased by 11.5% year-over-year, from -$74.91M to -$66.28M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s free cash flow?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s free cash flow has grown at a 6.1% compound annual growth rate (CAGR), from -$265.52M to -$336.24M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Iovance Biotherapeutics, Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude